October 11, 2024

Medical Trend

Medical News and Medical Resources

Novavax COVID-19 vaccines more than 85% effective against British variants!

Novavax COVID-19 vaccines more than 85% effective against British variants!



 

Novavax COVID-19 vaccines more than 85% effective against British variants!   

Novavax Inc announced that the test results show that the Novavax COVID-19 vaccine has an effective rate of 89.3% in preventing COVID-19 infections, and the effective rate of preventing infections of British variant strains has also exceeded 85%! Novavax shares soared 34%!

 

 

Novavax COVID-19 vaccines more than 85% effective against British variants!

 Novavax COVID-19 vaccines more than 85% effective against British variants!

 

When the outside world focused most of its attention on giant companies such as Pfizer Moderna, the “little-known” Novavax vaccine turned out with the latest test results.

 

It is worth noting that the vaccine company has set up two test sites in the UK and South Africa where highly infectious mutant viruses have been found.

 

Novavax said that in late-stage trials in the UK, more than 15,000 residents aged 18 to 84 participated, and about 27% of the subjects were 65 years of age or older.

The test was conducted during the spread of the highly infectious British strain. In the end, only 62 of these 15,000 subjects became ill.

About half of people who are sick are infected with the British variant strain B117.

 

Novavax COVID-19 vaccines more than 85% effective against British variants!


According to Novavax, the British test results show that the effective rate of two doses of Novavax COVID-19 vaccine against the original strain is 95.6%, while the effective rate against the British variant strain is 85.6%.

 

 

 

 

Test results were not so satisfactory in South Africa

 

The results of a South African trial involving 4400 volunteers showed that the Novavax COVID-19 vaccine is only 49.3% effective against the South African variant strain.

 

In South Africa, almost all of the infections analyzed in the Novavax trial were caused by the B1351 South African variant.

The data also shows that even if some people have been infected with COVID-19 before, they are still infected by the South African variant again.

 

Reuters pointed out that in the South African trial, the effective rate of Novavax’s COVID-19 vaccine can reach 60% for people who are not suffering from HIV/AIDS.

 

However, Novavax said the company will soon begin testing a new vaccine that will specifically target the South African variant to provide protection for the human body.

 

Some virus experts commented that although 50% is not as good as 100%, it is worse than 0%, and if the effective rate reaches 50%, it can meet the FDA approval standards. Based on the results of the British trial, the expert assessed that the effectiveness of Novavax vaccine should be comparable to that of Pfizer Moderna.

 

However, Pfizer and Moderna vaccines use RNA technology. Novavax uses a more traditional method of injecting coronavirus proteins to trigger an immune response.

 

 

 

 

 

Novavax COVID-19 vaccines more than 85% effective against British variants!

(source:internet, reference only)


Disclaimer of medicaltrend.org